Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/10/2018
SIETES contiene 92567 citas

 
 
 1 a 18 de 18 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Maya Y, Ota M. Drug-induced localised scleroderma. BMJ 2018;360:12 de abril. [Ref.ID 102643]
2. Cita con resumen
Vaidya JS, Massarut S, Vaidya HJ, Alexander EC, Richards T, Caris JA, Sirohi B, Tobias JS. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ 2018;360:j5913. [Ref.ID 102449]
4. Cita con resumen
Anónimo. Pertuzumab et cancers du sein métastasés. Prescrire 2017;37:94-5. [Ref.ID 101441]
5. Cita con resumen
Anónimo. Pertuzumab avant la chirurgie d'un cancer du sein. Prescrire 2017;37:92-4. [Ref.ID 101440]
6.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
8. Cita con resumen
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, for the CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34. [Ref.ID 98817]
9. Cita con resumen
Anónimo. Roche releases disappointing breast cancer drug data, discontinues Alzheimer’s study. DIA Daily 2014:19 de diciembre. [Ref.ID 98388]
10. Cita con resumen
Yeo B, Turner NC, Jones A. Medical management of breast cancer. BMJ 2014;348:g3608. [Ref.ID 98044]
12. Cita con resumen
Anónimo. Pertuzumab. Prescrire 2013;33:816. [Ref.ID 96493]
14. Cita con resumen
Anónimo. Briefing information for the September 12, 2013 Meeting of the Oncologic Drugs Advisory Committee Advisory Committee. FDA U.S. Food and Drug Administration 2013:12 de septiembre. [Ref.ID 96044]
15. Cita con resumen
Anónimo. Pertuzumab (Perjeta) for HER2-positive metastatic breast cancer. Med Lett Drugs Ther 2012;54:59-60. [Ref.ID 93492]
16.Tiene citas relacionadas
Gradishar WJ. HER2 therapy - An abundance of riches. N Engl J Med 2012;366:176-8. [Ref.ID 92211]
17.Tiene citas relacionadas Cita con resumen
Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Plenkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, for the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19. [Ref.ID 92209]
18.
Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298:70-82. [Ref.ID 80532]
Seleccionar todas
 
 1 a 18 de 18